Early-stage life science fund BioAdvance announced that it has added an array of new companies to its portfolio, investing nearly $3.2 million into companies from the mid-Atlantic region of the U.S. Two of the firm’s largest investments went to Opsidio, a Bryn Mawr, Penn.-based company developing monoclonal antibodies to treat fibrotic diseases, and New York-based […]
